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Summary  Most  patients  with  hypertrophic  cardiomyopathy  (HCM),  the  most  common  genetic
cardiac disease,  remain  asymptomatic,  but  others  may  suffer  from  sudden  cardiac  death.  A
better identification  of  those  patients  at  risk,  together  with  a  better  understanding  of  the
mechanisms  leading  to  arrhythmia,  are  crucial  to  target  high-risk  patients  and  provide  them
with appropriate  treatment.  However,  this  currently  remains  a  challenge.  In  this  paper,  we
present a  successful  example  of  implementing  computational  techniques  for  clinically-relevant
applications.  By  combining  electrocardiogram  and  imaging  data,  machine  learning  and  high
performance  computing  simulations,  we  identified  four  phenotypes  in  HCM,  with  differences  in
arrhythmic  risk,  and  provided  two  distinct  possible  mechanisms  that  may  explain  the  hetero-
geneity of  HCM  manifestation.  This  led  to  a  better  HCM  patient  stratification  and  understanding
of the  underlying  disease  mechanisms,  providing  a  step  further  towards  tailored  HCM  patient
management  and  treatment.
© 2019  The  Authors.  Published  by  Elsevier  Masson  SAS.  This  is  an  open  access  article  under  the
CC BY  license  (http://creativecommons.org/licenses/by/4.0/).VPH
Résumé  La  plupart  des  patients  atteints  de  cardiomyopathie  hypertrophique  (CMH),  une  mal-
adie cardiaque  génétique,  sont  souvent  asymptomatiques,  mais  cette  maladie  est  la  cause
première  de  mort  subite  chez  les  jeunes.  Une  meilleure  identification  des  patients  à  risque,
et une  meilleure  compréhension  des  mécanismes  responsables  des  arythmies  est  essentielle
∗ Corresponding author: Department of Computer Science, University of Oxford, Oxford, United Kingdom.
E-mail address: blanca.rodriguez@cs.ox.ac.uk (B. Rodriguez).
https://doi.org/10.1016/j.morpho.2019.09.001
1286-0115/© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
170  A.  Lyon  et  al.
pour  identifier  ces  patients  à  haut  risque  et  leur  fournir  un  traitement  approprié.  Cependant,
cela reste  un  défi.  Dans  cet  article,  nous  présentons  un  exemple  réussi  de  l’implémentation
de techniques  informatiques  pour  une  application  clinique.  En  associant  données  d’imagerie
et d’électrocardiographie,  machine  learning  et  modélisation  informatique,  nous  avons  iden-
tifié quatre  phénotypes  parmi  la  population  de  CMH,  présentant  différents  niveaux  de  risque
d’arythmie  et  de  mort  subite,  et  avons  proposé  deux  mécanismes  possibles  pour  expliquer
l’hétérogénéité  observée  dans  la  CMH.  Cette  étude  a  donc  amelioré  la  stratification  du  risque
chez les  patients  atteints  de  CMH  et  une  meilleure  compréhension  des  mécanismes  sous-jacent
à la  maladie,  fournissant  une  avancée  vers  une  prise  en  charge  individuelle  de  ces  patients  et
un traitement  personnalisé.
©  2019  Les  Auteurs.  Publié  par  Elsevier  Masson  SAS.  Cet  article  est  publié  en  Open  Access  sous


















































































ardiovascular  disorders  remain  a  major  burden  worldwide
nd  are  responsible  for  30%  of  deaths  in  the  world.  Among
hem,  hypertrophic  cardiomyopathy  (HCM)  is  a  genetic  car-
iac  disease  characterized  by  the  thickening  of  the  left
entricular  muscle  of  the  heart,  and  it  is  a  major  cause  of
udden  cardiac  death  (SCD),  especially  among  young  adults
nd  athletes  [1].  Most  patients  with  HCM  remain  asymp-
omatic  with  normal  life  expectancy,  but  some  of  them  may
ie  suddenly  of  cardiac  arrest  with  no  previous  signs.  Getting
 better  clinical  understanding  of  this  heterogeneous  clin-
cal  course  and  detect  high-risk  patients  to  provide  them
ith  appropriate  treatment  is  therefore  a  challenge  and  a
riority  in  the  management  of  HCM  [2].
HCM  hearts  suffer  from  structural  changes  such  as  hyper-
rophy  [3],  cardiomyocyte  disarray  [4],  fibrosis  [5], as  well
s  ion-channel  dysfunction  [6],  which  may  create  an  unsta-
le  electrical  milieu  predisposing  to  arrhythmia.  In  the  past,
on-invasive  tools  to  assess  the  heterogeneity  of  the  HCM
opulation  have  been  developed  based  on  the  electrocar-
iogram  (ECG)  [7,8],  but  they  lack  specificity  to  identify  the
atients  at  higher  risk  [9,10].  In  the  absence  of  reliable  ECG
iomarkers,  conventional  risk  factors  (non-sustained  ven-
ricular  tachycardia,  unexplained  syncope,  family  history
f  SCD,  massive  left  ventricular  hypertrophy  and  abnormal
xercise  blood  pressure  response)  are  also  used  to  eval-
ate  the  arrhythmic  risk  of  the  patients,  and  a  validated
CM  Risk-SCD  prediction  model  has  been  proposed  in  2014
11],  but  still  shows  limitations  [12].  Moreover,  these  clin-
cal  observations  do  not  capture  the  amount  of  underlying
yocardial  abnormalities  that  may  lead  to  arrhythmia,  and
he  pathophysiological  mechanisms  that  may  increase  HCM
isk  are  still  poorly  understood.
In  this  translational  case  study,  we  present  how  the  use
f  computational  methods  such  as  machine  learning  and
igh  performance  computing  simulations  helped  improve
he  risk  stratification  of  HCM  patients  and  shed  light  on  the
echanisms  underlying  the  HCM  disease.  Fig.  1  provides
n  overall  summary  of  the  findings  and  potential  clinical
mpact  of  the  case  study  presented  in  this  paper.  In  a  first
art,  we  report  how  the  development  of  a  clustering  algo-
ithm  based  on  novel  morphological  biomarkers  derived  from
he  ECG  helped  identify  four  distinct  phenotypes  among  the




isk  and  distribution  of  left  ventricular  hypertrophy.  In  a
econd  part,  we  show  how  the  use  of  high  performance
omputing  simulations  based  on  clinical  cardiac  magnetic
esonance  (CMR)  images  provided  mechanistic  understand-
ng  of  the  different  ECG  phenotypes,  and  helped  to  better
nderstand  the  heterogeneity  of  HCM.  This  paper  describes
ow,  by  developing  novel  computational  technologies  for
nalysis,  integration  and  augmentation  of  clinical  data,  we
ontributed  to  advancing  clinically-relevant  insight  into  HCM
nd  made  a  step  towards  individual  patient  management.
ethods and results
CG-based  morphological  markers  identify  four
istinct HCM  phenotypes  that  associate  with
ifferent arrhythmic  risk
n  the  first  part  of  this  project,  we  aimed  at  developing
athematical  modeling  and  machine  learning  methods  to
dentify  ECG  biomarkers  that  may  help  improve  the  under-
tanding  and  characterization  of  the  heterogeneity  of  the
CM  population  [13].
To  this  end,  we  analyzed  high-fidelity  ECG  recordings
rom  85  HCM  patients  and  38  healthy  volunteers  recruited
s  part  of  a  prospective  study  from  the  John  Radcliffe
ospital  in  Oxford,  UK.  12-lead  ECGs,  measuring  the  car-
iac  electrical  activity  from  twelve  different  perspectives
n  the  body  surface,  were  recorded  for  24  hours  using
olter  monitors.  CMR  imaging  was  also  performed  for  these
atients  and  provided  information  on  the  extent  and  dis-
ribution  of  the  hypertrophy.  Finally,  genetic  information,
onventional  risk  factors  and  family  history  were  obtained
s  part  of  routine  examination.  We  then  developed  signal
rocessing  and  mathematical  modeling  tools  to  compute
iomarkers  from  the  different  ECG  waves  in  order  to  char-
cterize  their  morphology.  We  focused  specifically  on  the
RS  complex,  representing  the  electrical  activation  of  the
entricles,  and  the  T  wave,  characterizing  ventricular  relax-
tion.  Standard  biomarkers  such  as  amplitude  and  width  of
he  waves  were  measured.  The  QRS  shape  was  also  charac-
erized  by  a combination  of  Hermite  basis,  well-established
athematical  functions  able  to  provide  a  compact  descrip-ion  of  the  QRS  complex.  Four  Hermite  functions  allowed
o  capture  HCM  heterogeneity,  and  each  patient  was  cha-
acterized  by  a  vector  of  morphological  QRS  and  T  wave
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Figure  1  Approach  and  clinical  impact  of  the  case-study.  Using  signal  processing,  mathematical  modeling  and  clustering,  we























abnormalities  in  HCMimproved patient  risk  stratification.  High  performance  simulat
phenotypes.  This  provided  new  options  for  individual  patient  m
biomarkers.  We  used  an  unsupervised  feature  selection
approach  combined  with  a  clustering  algorithm  to  investi-
gate  and  extract  subgroups  from  the  HCM  population.  This
was  performed  blinded  to  the  clinical  data.  Statistical  anal-
ysis  was  finally  performed  to  compare  the  risk  markers
between  the  groups.  Fig.  2  summarizes  the  methodological
approach  taken.
Based  on  QRS  morphology  only,  three  HCM  subgroups
were  identified.  Patients  in  Group  1  (52%  of  the  popula-
tion)  displayed  normal  QRS  morphology.  Group  2  (22%  of
patients)  showed  differences  in  the  first  three  Hermite  bases
in  lead  V4  compared  to  healthy  volunteers  and  Group  1,
but  no  differences  in  V6.  On  the  ECG,  this  was  observed
as  a  shorter  R  wave  duration  and  deeper  S  waves  in  lead
V4  compared  to  Group  1.  Group  3  (26%  of  patients)  exhib-
ited  large  differences  in  lead  II  and  V4—V6  compared  to  the
other  HCM  groups  and  healthy  volunteers,  more  specifically
short  R  wave  duration  and  amplitude,  and  longer  S  wave
duration  and  amplitude.  Among  these  three  groups,  ECG
features  were  therefore  significantly  different,  but  clinical
markers  and  markers  of  arrhythmic  risk  were  not.  This  sug-
gested  that  QRS  biomarkers  alone  were  not  sufficient  for
HCM  risk  stratification.
We then  combined  both  QRS  morphology  and  T  wave
biomarkers  in  the  clustering  algorithm.  This  led  to  the
identification  of  four  distinct  subgroups.  Groups  2  and
3  remained  the  same  than  the  ones  identified  with  QRS
T
p
then  investigated  the  potential  mechanisms  underlying  these
ement  and  different  therapeutic  approaches.
eatures  only.  However,  the  addition  of  the  polarity  of  the  T
ave  as  a  biomarker  separated  Group  1  into  Group  1A,  with
nverted  T  waves  in  leads  V4—V6,  and  Group  1B,  with  upright
 waves  in  these  leads  (Fig.  3, Panel  A).  Interestingly,  Group
A,  with  normal  QRS  morphology  but  inverted  T  waves,
howed  the  highest  median  HCM  Risk-SCD  score  among  the
our  groups  (Fig.  3, Panel  C).  Group  1A  also  exhibited  the
ost  patients  with  a mixed  hypertrophy  distribution,  with
ombined  septal  and  apical  hypertrophy,  while  Groups  2
nd  3  had  mostly  septal  hypertrophy  only.  Group  1B  patients
xhibited  little  to  no  hypertrophy  (Fig.  3,  Panel  B).
This  study  therefore  identified  four  distinct  HCM  phe-
otypes  based  on  newly  developed  ECG  morphological
iomarkers  extracted  from  high-fidelity  recordings.  Such
henotypes  showed  differences  in  arrhythmic  risk  scores  and
istribution  of  left  ventricular  hypertrophy.  Thus,  our  study
howed  the  potential  of  using  ECG  phenotyping  combined
ith  machine  learning  to  dissect  the  heterogeneity  of  HCM
nd  help  improve  individual  patient  management.
igh  performance  computer  simulations  based  on
MR images  provide  different  mechanisms  for  ECGhe  previous  study  identified  four  subgroups  in  the  HCM
opulation  that  showed  differences  in  arrhythmic  risk  and

































Figure  2  Methodological  approach  to  the  id
istribution  of  hypertrophy.  Following  up  on  this  work,  our
ext  objective  was  to  understand  the  mechanisms  behind
uch  a  phenotypic  heterogeneity,  and  provide  potential
xplanations  for  the  different  subgroups  identified  [14].
linically,  improving  the  mechanistic  understanding  of  HCM
ay  yield  a  key  impact  on  the  individual  management  of
hese  patients,  including  potential  treatment  and  tailored
herapies.
To  this  end,  we  developed  a  high  performance  com-
uter  simulation  framework  based  on  CMR  imaging  data.
e  selected  representative  patients  from  Group  1A  (with
ormal  QRS  morphology  and  inverted  T  waves,  and  high-
st  risk  score  for  sudden  cardiac  death),  Group  1B  (with
ormal  ECG  morphology)  and  Group  3  (with  abnormal  QRS,
ormal  T  wave,  and  second  highest  risk  score).  From  the
MR  images  of  these  patients,  we  computed  a  personal-
zed  volumetric  mesh  of  each  patient’s  heart  and  torso.  The




fication  of  four  HCM  phenotypes  (from  [13]).
y  implementing  a  cellular  computational  action  potential
odel  [15]  at  each  node  of  the  volumetric  mesh,  to  simu-
ate  propagation  of  the  electrical  signal.  Virtual  electrodes
ere  additionally  modelled  to  record  the  simulated  ECG  on
he  virtual  patients.  With  this  simulation  framework,  our  aim
as  to  reproduce  the  ECG  abnormalities  identified  in  the  dif-
erent  HCM  phenotypes  of  the  previous  study,  and  provide
otential  mechanistic  explanations  for  this  ECG  heterogene-
ty  using  computer  simulations.  We  therefore  evaluated  the
nfluence  of  various  abnormalities  reported  in  HCM  on  the
CG  morphology,  including  increased  wall  thickness,  car-
iomyocyte  fiber  disarray,  changes  in  conduction  velocity,
onic  remodeling  or  abnormal  coupling  between  the  Purkinje
ast  conduction  layer  and  the  myocardium.These  different  simulations  allowed  us  to  investigate  the
ndividual  effects  of  these  HCM  abnormalities  on  the  ECG
nd  identify  those  that  may  be  responsible  for  the  HCM  phe-
otypes  identified.  The  distribution  of  hypertrophy  and  the






Figure  3  Four  phenotypes  were  identified  in  HCM,  exhibiting
and arrhythmic  risk  (C)  (from  [13]).
anatomy  of  the  patient  yielded  similar  QRS  morphology  and
normal  T  waves  in  all  cases  (Fig.  4).  Therefore,  increased
wall  thickness  could  not  explain  the  QRS  and  T  wave  abnor-
malities  observed  in  Groups  1A  and  3.  We  then  focused  on
the  impact  of  tissue  microstructure  on  the  ECG,  and  eval-
uated  the  effect  of  fiber  disarray  and  altered  conduction
velocity  due  to  fibrosis  or  hypertrophy  in  various  regions  of





rences  in  ECG  morphology  (A),  distribution  of  hypertrophy  (B)
o  abnormal  QRS  complexes,  but  did  not  translate  into  the
pecific  deep  S  waves  in  lead  V6  that  characterized  Group  3
Fig.  5).  We  then  focused  on  the  influence  of  altering  the
onduction  system  by  modifying  the  activation  sequence
f  the  ventricles,  and  the  coupling  between  the  Purkinje
ndocardial  layer  and  the  myocardium.  Simulating  various
onduction  blocks  affected  the  QRS  complexes  morphology
ut  did  not  lead  to  the  abnormalities  of  Group  3  (Fig.  6).
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illustrated  in  our  case  study,  the  power  of  these  techniquesigure  4  Effect  of  the  anatomy  on  the  ECG.  Groups  1B,  3  and
nd distribution  of  hypertrophy.  Anatomy  alone  does  not  explai
owever,  modeling  an  abnormal  coupling  between  the  fast
ndocardial  layer  and  the  myocardium  was  the  only  way  to
imulate  the  deep  S  waves  in  leads  V4—V6  identified  in  Group
 (Fig.  7,  Panel  D),  by  creating  a  patchy  electrical  activation
ith  areas  of  late  activation  (Fig.  7,  Panels  A  to  C).  Finally,
e  modelled  the  HCM  ionic  remodeling  (Fig.  8),  including  an
ncrease  of  the  late  sodium  and  the  L-type  calcium  currents,
 reduction  of  the  potassium  currents,  and  remodeling  of
he  calcium  handling  subsystem,  in  hypertrophic  areas.  This
ed  to  a  prolonged  duration  of  the  action  potential  in  these
egions  and  translated  into  inversed  T  waves  on  the  lateral
eads  of  the  ECG,  explaining  the  phenotype  of  Group  1A.
hese  simulations  therefore  identified  two  distinct  poten-
ial  mechanisms  for  the  ECG  abnormalities  associated  with
n  increased  risk  of  SCD  in  HCM.  They  also  suggested  that
he  HCM  ionic  remodeling  expressed  in  Group  1A,  subgroup
ith  the  highest  SCD  risk  score,  may  play  a  key  role  in
rrhythmogenesis.  The  nature  of  these  mechanisms  is  very
ifferent:  one  is  based  on  conduction  abnormalities,  while
he  other  involves  ionic  remodeling.  This  has  implications  on




exhibit  similar  ECG  morphologies  despite  differences  in  extent
up  3  and  1A  specific  abnormalities.  Taken  from  [14].
ndeed,  while  Group  1A  may  benefit  from  a  pharmacological
reatment  targeting  the  expression  of  ion  channels,  Group  3
ay  not  respond  to  such  therapy.
iscussion
ombining  computational  methods  improves  the
linical  understanding  of  cardiac  diseases
n  this  paper,  we  report  an  example  of  successful  imple-
entation  of  computational  technology  for  a  clinical
pplication  in  cardiology.  The  computational  methods
onsidered  here  combine  signal  processing,  mathematical
odeling,  machine  learning  and  high  performance  com-
uting,  and  they  contribute  to  untangle  the  heterogeneity
f  HCM  and  provided  more  insight  in  its  mechanisms.  Ass  twofold.  Firstly,  they  are  able  to  make  sense  of  multi-
ariate,  complex  and  heterogeneous  datasets  and  detect
ifferences  that  might  be  challenging  for  the  human  eye





Figure  5  Effect  of  conduction  changes  in  various  re
[16].  These  techniques  make  fewer  assumptions  by  selecting
discriminatory  features  from  the  whole  ECG  data.  With  the
growing  amount  of  recorded  data  in  clinical  settings,  the
integration  of  these  methods  in  the  clinic  may  be  crucial  to
aid  healthcare  decisions  and  improve  patient  stratification




 of  the  myocardium  on  the  QRS  complex  (from  [14]).
s  computer  modeling,  allow  the  independent  assessment
f  the  influence  of  individual  parameters  forming  a  system.
his  is  a  key  strength  compared  to  standard  experimental
echniques,  for  which  isolating  parameters  to  study  their
ffect  remains  a  challenge.  As  a  consequence,  compu-
ational  techniques  are  receiving  a  growing  attention









As  mentioned  previously  in  the  text,  this  work  showed  clin-
ical  implications  in  two  ways.  First,  it  provided  a  newFigure  6  Effect  of  activation  blocks  in  various  reg
o  analyze  medical  data  and  address  clinical  problems
17—19],  and  despite  that  several  challenges  remain,
ostly  due  to  the  nature  of  real-world  data  (print-out
CGs,  incomplete  datasets,  need  for  expert  consensus),
hey  can  help  uncover  new  mechanisms,  improve  disease
nowledge,  guide  therapies  and  aid  clinical  decisions.
c
v
f  the  myocardium  on  the  QRS  complex  (from  [14]).
linical  impact  of  the  worklassification  of  HCM  patients  based  on  ECG  biomarkers,  pro-
iding  insight  in  the  heterogeneity  of  the  disease.  We  showed
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Figure  7  Abnormal  Purkinje-myocardium  coupling  led  to  a  patchy  activation  (A,  B)  with  areas  of  late  activation  (C),  and  translated
















that  HCM  patients  with  a  primary  T  wave  inversion  (and
normal  QRS)  have  a  greater  risk  of  SCD  and  arrhythmia,  com-
pared  to  patients  with  solely  QRS  abnormalities,  highlighting
the  key  role  of  repolarization  in  arrhythmogenesis  in  HCM.
We  also  showed  that  the  location  and  distribution  of  hyper-
trophy  was  associated  to  higher  SCD  risk,  rather  than  the
extent  of  hypertrophy.  Secondly,  the  use  of  computer  simu-
lations  provided  two  distinct  mechanisms  that  may  explain
the  different  phenotypes  we  identified  in  HCM.  Abnormal
Purkinje  conduction  can  explain  the  QRS  abnormalities  of
Group  3,  while  HCM  ionic  remodeling  in  the  region  of  hyper-
trophy  may  be  responsible  for  inverted  T  waves  in  Group
1A.  The  fact  that  Group  1A  displayed  the  highest  SCD  risk
score  suggested  that  ionic  remodeling  in  HCM  may  play  a
key  role  in  arrhythmogenesis,  while  the  conduction  abnor-
malities  in  the  Purkinje  system  may  be  less  proarrhythmic.
Finally,  this  overall  better  understanding  of  HCM  hetero-
geneity  may  have  implications  in  patient  management,  as
personalized  treatment  for  HCM  patients  could  be  provided
depending  on  the  mechanisms  underlying  their  ECG  abnor-





 pharmacological  treatment  improving  ion  channels  func-
ion,  while  this  would  have  no  effect  on  a  patient  of  Group
.
urrent  and  potential  developments  of  the  work
evelopments  of  the  work  presented  in  this  paper  are  cur-
ently  ongoing.  A  new  database  of  HCM  ECG  recordings  is
eing  collected  and  will  enable  the  application  of  the  mod-
ling  and  clustering  technology  on  a  larger  dataset.  This
ill  allow  us  to  evaluate  the  ECG  criteria  presented  in
he  study  on  a  larger  cohort  with  a  larger  number  of  car-
iovascular  end-points  and  events.  This  could  lead  to  the
efinition  of  a  new  classification  criterion  used  in  the  clinic
or  visual  inspection  of  ECGs  in  HCM.  Moreover,  this  work
enerated  strong  motivation  for  deeper  clinical  investiga-
ions,  such  as  the  use  of  endocardial  or  epicardial  mapping
tudies  to  verify  the  hypothesis  presented  here  for  the  mech-
nisms  responsible  for  the  HCM  phenotypes.  The  use  of  new
echnologies  such  as  ECG  imaging  may  add  even  more  infor-
ation  to  these  findings.















igure  8  HCM  ionic  remodeling  in  various  regions  of  the  myo
he inverted  T  waves  with  normal  QRS  observed  in  Group  1A  pa
onclusion
n  this  paper,  we  describe  the  successful  integration  of  com-
utational  techniques  to  improve  the  clinical  understanding
f  HCM.  By  combining  ECG  and  CMR  imaging  data  with
athematical  modeling,  clustering  and  high  performance
omputing,  we  identified  four  distinct  HCM  phenotypes  with
ifferences  in  arrhythmic  risk  score,  and  proposed  two  dif-
erent  mechanisms  that  may  explain  this  heterogeneity  at
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he  tissue  level.  This  work  therefore  had  impact  on  person-
lized  HCM  patient  management  and  risk  stratification,  as
ell  as  on  knowledge  and  mechanistic  understanding  of  the
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